Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Bench to Bedside Licensing Einstein technology: the inside story ReseARch
Document related concepts
no text concepts found
Transcript
Science at the heart of medicine Albert Einstein College of Medicine o f y e s h i v a u n i v er s i t y Bench to Bedside Licensing Einstein Technology: The Inside Story Research ! is currently in clinical trials with an Einstein technology, ! a new drug candidate intended to treat Metastatic Melanoma (MM) Join us for a panel discussion with the following key participants in this developing story: • Remi Barbier, CEO of Pain Therapeutics, Inc. • Dr. Ekaterina Dadachova, representing the Binding to 6D2 antibody to dead melanoma cells. Dead cell is shown with an arrow head. Matching immunofluorescent image is on the bottom. Einstein inventors (other co-inventors include Dr. Arturo Casadevall and Dr. Joshua Nosanchuk) • John Harb, Director of the Office of Biotechnology Dr. Edward Burns, Executive Dean, will serve as the moderator. Thursday, September 24th at 1 PM Price Center/Block Research Pavilion (LeFrak Auditorium) ! ! Light refreshments will be served at the start of the event. Co-Sponsored by: The Offices of Biotechnology & Business Development The Department of Microbiology & Immunology Mice treated with 188Rhenium-labeled 6D2 antibody. Treated mouse is on the top. The tumor has disappeared and only melanin pigment is seen under the skin. On the bottom – untreated control mouse.
